Join to View Full Profile
234 Goodman StMail Location 0796Cincinnati, OH 45219
Phone+1 513-584-1000
Dr. Mathieu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2006 - 2009
Meharry Medical CollegeClass of 2005
Certifications & Licensure
MD State Medical License 2010 - 2025
Publications & Presentations
PubMed
- 12 citationsFDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.Luckson N Mathieu, Erin Larkins, Arup K Sinha, Pallavi S Mishra-Kalyani, Samina Jafri
Clinical Cancer Research. 2023-08-15 - 41 citationsFDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, Luckson N Mathieu, Yi Ren
Clinical Cancer Research. 2022-06-01 - 70 citationsFDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or AlterationsLuckson Mathieu, Erin Larkins, Oladimeji Akinboro, Pourab Roy, Anup K. Amatya
Clinical Cancer Research. 2021-08-03
Press Mentions
FDA Roundup: September 13, 2024September 13th, 2024- Oncologists Discuss ‘Magic Wand’ Solutions to Improve Clinical Trial DiversityMarch 17th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
